Drug firm Zydus Cadila has received approval from the US health regulator to market its Pyridostigmine Bromide Tablets, used for treating various neurological disorders.
With this approval, the group has received 100 approvals and has so far filed 260 ANDAs (abbreviated new drug applications).
The company has received final approval from the US Food and Drug Administration (USFDA) to market Pyridostigmine Bromide Tablets USP, 60 mg, Zydus Cadila said in a filing to BSE.
According to IMS Health data, the estimated sales in 2015 for these tablets was USD 27.9 million.
Shares of Zydus Cadila were trading at Rs 1,774.50 on BSE, up 2.48 per cent in the early morning trade.
